MabVax Therapeutics Holdings, Inc.
Ticker Symbol: USOTC:MBVXQ
OTC Market Tier: Pink No Information
CIK Number: 0001109196
Security Type: Common Stock
MBVXQ Address: 11535 Sorrento Valley Rd.
Suite 400
San Diego, California 92121
MBVXQ Country: USA
MBVXQ Phone: (858) 259-9405
MBVXQ Fax #: N/A
Website: http://www.mabvax.com
Description: MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products and vaccines to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax also has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. In December 2015 MabVax received authorization from the U.S. Food and Drug Administration, or FDA, to proceed with initiation of a Phase I clinical trial with HuMab-5B1 MVT-5873 as a therapeutic treatment for pancreatic cancer. Patient enrollment in the Phase I clinical trial was initiated in the first quarter of 2016. In February 2016 MabVax announced the FDA had provided authorization to proceed with [Zr-89]-HuMab-5B1 MVT-2163, utilizing our fully human antibody product as a new generation PET scan cancer imaging agent. We expect patient enrollment for the new generation PET scan cancer imaging agent to begin in the second quarter of 2016. MabVax also has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof-of-concept Phase II multicenter clinical trials. Additional information is available at www.mabvax.com.
SIC Code / Description: 2834 / Pharmaceutical preparations
Shares Authorized: 150,000,000
Shares Outstanding: 9,254,582
Shares Outstanding Date: 10/16/2018
Shares Holder Count: 105
Shares Holder Date: 04/02/2018
Market Capitalization: $ 185,091.64
Key Executives: Kenneth Cohen - Dir.
Paul Maier - Dir.
Jeffrey Ravetch - Dir.
Robert Hoffman - Dir.
Jeffrey Eisenberg - Dir.
Paul Maffuid - EVP
J. David Hansen - CEO
Gregory Hanson - CFO
Philip Livingston - Dir.
Tamara Kelly - Accountant
Number of Employees: 20
Incorporation State: DE
Incorporation Country: USA
Incorporation Year: 1988
Auditor: Haskell & White LLP
Auditor Address: 300 Spectrum Drive
Suite 300
Irvine, CA 92618
United States
Auditor Website: http://https://www.hwcpa.com/
IR Firm: LHA
IR Firm Address: N/A
IR Firm Website: http://https://www.hwcpa.com/
Legal Counsel: Mintz, Levin, Cohen, Ferris, Glovsky and Popeo, P.C.
Legal Counsel Address: 3580 Carmel Valley Road
3580 Carmel Valley Road
San Diego, CA 92130
USA
Legal Counsel Website: www.mintz.com
Fiscal Year End: 12/31
Reporting Status: Alternative Reporting Standard
Bankrupt: Yes
Shell: No
Audit Status: Yes
ADR Ratio: N/A
Transfer Agent: Computershare U.S.
TA Address: 150 Royall Street
Canton, MA 02021
USA
Depository Website: N/A
SHO Flag: N/A
3210 Flag: N/A
Short Volume: 303
Short Date: 06/28/2019
Closing MMID: 10
BFCMmid: 6
Tier ID: 22
Status: Active


Your Recent History
USOTC
MBVXQ
MabVax The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.